Takeda Pharmaceutical Company (4502) Q1 2025 earnings summary

Executive summary

• Q1 FY2024 revenue grew 2.1% at constant exchange rates (CER) and 14.1% reported, with growth and launch products up 17.8% at CER, now representing 46% of total revenue.

• Core operating profit margin reached 31.6%, aided by R&D phasing, OPEX reduction, and slower-than-expected Vyvanse generic erosion; reported margin was 13.8% due to restructuring and impairment costs.

• Net profit increased 6.5% year-over-year to JPY 95.2 billion (reported), while core EPS rose 17.5% to JPY 176.

• Operating cash flow surged 84.3% to JPY 170.3 billion; adjusted free cash flow turned positive at JPY 23.7 billion from negative JPY 207.5 billion last year.

• Pipeline and portfolio expansion continued, with two option agreements signed for mid/late-stage assets in oncology and Alzheimer's.

Financial highlights

• Q1 revenue was JPY 1,208.0 billion (+14.1% reported, +2.1% CER), driven by growth and launch products and favorable FX.

• Core operating profit was JPY 382.3 billion (+17.1% reported, +4.5% CER); reported operating profit was JPY 166.3 billion (-1.3% year-over-year) due to restructuring and impairment.

• Core EPS was JPY 176; reported EPS was JPY 61.

• Operating cash flow was JPY 170.3 billion; adjusted free cash flow was JPY 23.7 billion, reflecting significant business development spend.

• Gross margin was 68.0% in Q1, down 1.7pp year-over-year, expected to decline to 65.5% for the full year due to product mix shifts.

Outlook and guidance

• Full-year FY2024 outlook remains unchanged; revenue forecast JPY 4,350.0 billion (+2.0%), core operating profit JPY 1,000.0 billion (-5.2%), and core EPS JPY 431.

• Net profit is projected to decline 59.7% to JPY 58.0 billion, mainly due to higher expenses and accelerated Vyvanse generic erosion.

• R&D investments expected to increase in coming quarters as multiple programs move into phase III.

• Guidance will be updated at Q2 earnings if necessary.

• Management expects core revenue flat to slightly declining at CER, with core operating profit and EPS down.